Zenas Biopharma Inc

ZBIONASDAQ · USD
26.95USD0.00 (-2.00%)
1110

Zenas Biopharma Inc (ZBIO) Option Chain

As of September 24, 2026, Zenas Biopharma Inc is trading at $26.95, a -2.00% change from the previous close. The nearest expiration is Oct 16, 2026. Implied volatility is 104.8%. IV Rank is 43%.

Read more

Tracking the ZBIO option chain helps you see every strike and expiry on Zenas Biopharma Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Zenas Biopharma Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of ZBIO options activity at a glance. Use our scanner to monitor the ZBIO option chain in real time and filter for the ZBIO options trades that actually meet your criteria.

An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For ZBIO stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the ZBIO option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where ZBIO stock options are being actively traded and where they are not.

Zenas BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody for various indications, including immunoglobulin G4-related disease, multiple sclerosis, systemic lupus erythematosus, and warm autoimmune hemolytic anemia. The company also develops ZB002, an anti-TNFa monoclonal antibody; ZB004, a cytotoxic T-lymphocyte-associated antigen 4-immunoglobulin fusion; ZB001, an anti-insulin-like growth factor-1 receptor monoclonal antibody; and ZB005, an anti-active complement component 1s monoclonal antibody.

Zenas BioPharma, Inc. was formerly known as Zenas BioPharma (Cayman) Limited and changed its name to Zenas BioPharma, Inc. in August 2023. The company was incorporated in 2019 and is based in Waltham, Massachusetts.

Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Zenas Biopharma Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen ZBIO options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of ZBIO stock options — let the full option chain come to you, pre-filtered and ready to trade.

Stock Statistics

  • IndustryBiotechnology
  • SectorHealthcare
  • IV percentile82.14% Elevated
  • Market cap (M$)1,757
  • 52 weeks high-39.57%
  • 52 weeks low99.63%
  • Analyst recommendationStrong Buy
    1.25
  • Target price$47.00
    74.40% above the current stock price
  • Dividend—
  • Payout ratio—
  • Earnings date2026-11-12
  • P/E—
  • Future P/E—
  • EPS (ttm)-9.61
  • EPS growth next 5 years22.18%

As of September 24, 2026

2026-10-16
5 strikes
Default
CALLsPUTs
Prob. OTM %Open InterestVolumeExtrinsic ValueIntrinsic ValueBidAskStrikeMoneyness %BidAskIntrinsic ValueExtrinsic ValueVolumeOpen InterestProb. OTM %
16.69000.456.955.009.8020.00-27.27—4.900.004.900083.31
28.82000.654.453.007.2022.50-18.18—4.900.004.900071.18
42.32001.201.951.005.3025.00-9.09—3.500.003.500257.68
66.91104.900.00—4.9030.00+9.091.805.803.050.750133.09
83.43804.900.00—4.9035.00+27.276.3010.008.050.100116.57

As of September 24, 2026

Scan the full option chain in one place

Browse the full ZBIO option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.

Start your 14-day free trial